BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sancak S, Hardt A, Singer J, Klöppel G, Eren FT, Güllüoglu BM, Sen LS, Sever Z, Akalin NS, Eszlinger M, Paschke R. Somatostatin Receptor 2 Expression Determined by Immunohistochemistry in Cold Thyroid Nodules Exceeds That of Hot Thyroid Nodules, Papillary Thyroid Carcinoma, and Graves' Disease. Thyroid 2010;20:505-11. [DOI: 10.1089/thy.2009.0203] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Mu ZZ, Zhang X, Lin YS. Identification of Radioactive Iodine Refractory Differentiated Thyroid Cancer. Chonnam Med J 2019;55:127-35. [PMID: 31598469 DOI: 10.4068/cmj.2019.55.3.127] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
2 Salavati A, Puranik A, Kulkarni HR, Budiawan H, Baum RP. Peptide Receptor Radionuclide Therapy (PRRT) of Medullary and Nonmedullary Thyroid Cancer Using Radiolabeled Somatostatin Analogues. Seminars in Nuclear Medicine 2016;46:215-24. [DOI: 10.1053/j.semnuclmed.2016.01.010] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 5.8] [Reference Citation Analysis]
3 Woelfl S, Bogner S, Huber H, Salaheddin-Nassr S, Hatzl M, Decristoforo C, Virgolini I, Gabriel M. Expression of somatostatin receptor subtype 2 and subtype 5 in thyroid malignancies. Nuklearmedizin 2014;53:179-85. [PMID: 24967740 DOI: 10.3413/Nukmed-0646-14-02] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
4 Versari A, Sollini M, Frasoldati A, Fraternali A, Filice A, Froio A, Asti M, Fioroni F, Cremonini N, Putzer D, Erba PA. Differentiated Thyroid Cancer: A New Perspective with Radiolabeled Somatostatin Analogues for Imaging and Treatment of Patients. Thyroid 2014;24:715-26. [DOI: 10.1089/thy.2013.0225] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 5.5] [Reference Citation Analysis]
5 Kundu P, Lata S, Sharma P, Singh H, Malhotra A, Bal C. Prospective evaluation of 68Ga-DOTANOC PET-CT in differentiated thyroid cancer patients with raised thyroglobulin and negative 131I-whole body scan: comparison with 18F-FDG PET-CT. Eur J Nucl Med Mol Imaging 2014;41:1354-62. [DOI: 10.1007/s00259-014-2723-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
6 Treglia G, Rindi G, Rufini V. Expression of somatostatin receptors may guide the use of somatostatin receptor imaging and therapy in differentiated thyroid cancer. Hormones (Athens) 2012;11:230-2. [PMID: 22908057 DOI: 10.1007/BF03401532] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]